Livedoid skin reaction probably dye to imatinib therapy

Annals of Pharmacotherapy

Volumn 41, Issue 1, 2007, Pages 148-152

  Martínez González, M Covadonga ^a   Del Pozo, Jesús ^a   Yebra Pimentel, María Teresa ^a   Pérez, Mónica ^a   Almagro, Manuel ^a   Fonseca, Eduardo ^a  

^a HOSPITAL JUAN CANALEJO   (Spain)

Author keywords

Imatinib; Livedoid pattern; Skin rash

Indexed keywords

ALLOPURINOL; ALPHA INTERFERON; ASPARAGINASE; BCR ABL PROTEIN; BUSULFAN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; FUROSEMIDE; HYDROCORTISONE; HYDROXYUREA; IMATINIB; METHOTREXATE; PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; CASE REPORT; CAUSE OF DEATH; CHEMOSIS; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; CORTICOSTEROID THERAPY; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ERYTHEMA; EYELID EDEMA; HUMAN; HUMAN TISSUE; ISCHEMIA; LEG EDEMA; MALE; NARANJO PROBABILITY SCALE; PATIENT MONITORING; PERIORBITAL EDEMA; PERIPHERAL NEUROPATHY; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; RASH; RATING SCALE; RECURRENCE RISK; REMISSION; SEPTIC SHOCK; SKIN BIOPSY; SKIN PRURITUS; SYSTEMIC THERAPY; TREATMENT OUTCOME;

ADULT; AGED; DRUG ERUPTIONS; EXANTHEMA; HUMANS; MALE; PIPERAZINES; PYRIMIDINES;

EID: 33846448177     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1H304     Document Type: Article

References (20)

1. Cervantes F, Hernandez-Boluda JC, Odriozola J, et al. Imatinib mesylate (STI571) treatment in patients with chronic-phase chronic myelogenous leukaemia previously submitted to autologous stem cell transplantation. Br J Haematol 2003;120:500-4.
2. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukaemia. N Engl J Med 2001;344:1031-7.
3. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-42.
4. Ikegame K, Mukouchi C, Kunitomi A, et al. Successful treatment of bcr/abl-positive acute mixed lineage leukemia by unmanipulated bone marrow transplantation from an HLA-haploidentical (3-antigen-mismatched) cousin. Bone Marrow Transplant 2003;31:1165-8.
5. Berger U, Hehlmann R. Imatinib-new, molecular therapeutic possibility in chronic myeloid leukemia. The IRIS Study. Internist (Berl) 2004;45:102-3.
6. O'Brien SG, Guilhot F, Larson RA, et al. IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
7. Schienfeld N. A comprehensive review of imatinib mesylate (Gleevec) for dermatological diseases. J Drugs Dermatol 2006;5:117-22.
8. Severino G, Chillotti C, De Lisa R, Del Zompo M, Ardau R. Adverse reactions during imatinib and lansoprazole treatment in gastrointestinal stromal tumors. Ann Pharmacother 2005;39:162-4. Epub 2004 Nov 16. DOI 10.1345/aph1.E127
9. Ugurel S, Hildenbrand R, Dippel E, Hochhaus A, Schadendorf D. Dose-dependent severe cutaneous reactions to imatinib. Br J Cancer 2003;88:1157-9.
10. Breccia M, Carmosino I, Russo E, Morano SG, Latagliata R, Alimena G. Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib. Eur J Haematol 2005;74:121-3.
11. Roux C, Boisseau-Garsaud AM, Saint-Cyr I, Helenon R, Quist D, Delaunay C. Lichenoid cutaneous reaction to imatinib. Ann Dermatol Veneol 2004;131:571-3.
12. Scheinfeld N. Imatinib mesylate and dermatology part 2: a review of the cutaneous side effects of imatinib mesylate. J Drugs Dermatol 2006;5:228-31.
13. Brouard M, Saurat JH. Cutaneous reactions to STI571. N Engl J Med 2001;345:618-9.
14. Valeyrie L, Bastuji-Garin S, Revuz J, et al. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients. J Am Acad Dermatol 2003;48:201-6.
15. Drummond A, Micallef-Eynaud P, Douglas WS, Hay I, Holyoake TL, Drummond MW. A spectrum of skin reactions caused by the tyrosine kinase inhibitor imatinib mesylate (STI 571, Glivec). Br J Haematol 2003;120:911-3.
16. Hamm M, Touraud JP, Mannone L, Klisnick J, Ponnelle T, Lambert D. Imatinib-induced purpuric vasculitis. Ann Dermatol Venereol 2003;130:765-7.
17. Clark SH, Duvic M, Prieto VG. Mycosis fungoides-like reaction in a patient treated with Gleevec. J Cutan Pathol 2003;30:279-81. Erratum 2004;31:81.
18. Gambacorti-Passerini C, Tornaghi L, Cavagnini F, et al. Gynaecomastia in men with chronic myeloid leukaemia after imatinib. Lancet 2003;361:1954-6.
19. Van de Voorde K, De Raeve H, Van Regenmortel N, Lambert J. Imatinib-induced eccrine squamous syringometaplasia. J Am Acad Dermatol 2006;55:S58-9.
20. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.